SeraNovo and AstraZeneca to Collaborate on Research Projects

SeraNovo (Leiden, The Netherlands) is pleased to announce the closing of a multi-compound deal with AstraZeneca (Cambridge, United Kingdom).SeraNovo (Leiden, The Netherlands) is pleased to announce the closing of a multi-compound deal with AstraZeneca (Cambridge, United Kingdom).

Niall Hodgins, Chief Executive Officer of SeraNovo commented:“SeraNovo has grown substantially in recent years in terms of our technical capabilities and worldwide customer base. It is great to be able to share news of one of our most important collaborations with such a historic company. Our technology will again be used to drive important therapies to patients. We look forward to a long and prosperous relationship with AstraZeneca.”

About SeraNovo

SeraNovo is a formulation technology provider that enhances the bioavailability of poorly soluble Active Pharmaceutical Ingredients (APIs). Our team specializes in addressing two core issues with our proprietary technology: enhancing bioavailability and reducing development time to the clinic. As the inventor of this technology, SeraNovo owns the associated know-how and intellectual property.SeraNovo is a formulation technology provider that enhances the bioavailability of poorly soluble Active Pharmaceutical Ingredients (APIs). Our team specializes in addressing two core issues with our proprietary technology: enhancing bioavailability and reducing development time to the clinic. As the inventor of this technology, SeraNovo owns the associated know-how and intellectual property.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.